drugset / Trial / NCT01148498
A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The purpose of this trial is to compare the average change in the amount of amyloid beta species in blood after an infusion of solanezumab.
Timeline
- Start
- 2010-08
- Primary completion
- 2012-08
- Completion
- 2012-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Solanezumab | Protein / enzyme biologic | 400 mg | Intravenous |